Genetic Technologies (GENE) has released an update.
Genetic Technologies Limited has launched a clinical study to integrate its geneType Breast Cancer Risk Assessment Test in major U.S. breast imaging centers, aiming to enhance personalized medicine and screening compliance. The innovative study, involving top clinicians, seeks to streamline breast cancer care by incorporating genetic risk assessment into patient management. This move could revolutionize breast cancer screening and risk-reduction strategies, potentially affecting 68 million women within the screening age range in the U.S.
For further insights into GENE stock, check out TipRanks’ Stock Analysis page.
